We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comment on "Toxic epidermal necrolysis during camrelizumab treatment for oesophageal squamous cell carcinoma".
- Authors
Ruan, Yeping; Shih, Yanting; Chen, Shile; Xia, Qunli; Zhao, Xiaoqing; Cao, Hua
- Abstract
Similar phenomenon was also observed in ICIs-related bullous pemphigoid.10 In conclusion, we provided more evidence that anti-SSA antibody was found in TEN patients triggered by anti-PD1 therapy. Anti-SSA/Ro antibody is the most prevalent antibody to extractable nuclear antigen, often identified in patients with Sjögren's syndrome, systemic lupus erythematosus (SLE) and other autoimmune diseases. Keywords: anti-PD1 immunotherapy; anti-SSA antibody; immune checkpoint inhibitors; Ro-52; toxic epidermal necrolysis EN anti-PD1 immunotherapy anti-SSA antibody immune checkpoint inhibitors Ro-52 toxic epidermal necrolysis 387 388 2 09/08/22 20221001 NES 221001 We read with great interest the article 'Toxic epidermal necrolysis during camrelizumab treatment for oesophageal squamous cell carcinoma' by Peng et al.,1 presenting a case of a man who developed toxic epidermal necrolysis (TEN) during treatment with camrelizumab and in whom antinuclear antibodies were detected.
- Subjects
TOXIC epidermal necrolysis; SQUAMOUS cell carcinoma; IMMUNE checkpoint inhibitors; SJOGREN'S syndrome; SATELLITE cells; IMMUNE checkpoint proteins
- Publication
Contact Dermatitis (01051873), 2022, Vol 87, Issue 4, p387
- ISSN
0105-1873
- Publication type
Article
- DOI
10.1111/cod.14179